Who are DAPT, Statin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): prasugrel or ticagrelor, Prasugrel Oral Tablet, Acetylsalicylic Acid + clopidogrel, enoxaparin + clopidogrel + aspirin, clopidogrel (SR25990C), heparin + clopidogrel + aspirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapt-statin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DAPT, Statin — Competitive Intelligence Brief

DAPT, Statin (DAPT, Statin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet. Area: Cardiovascular.

phase 2 Antiplatelet P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

DAPT, Statin (DAPT, Statin) — Samsung Medical Center. DAPT inhibits platelet aggregation by blocking the P2Y12 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DAPT, Statin TARGET	DAPT, Statin	Samsung Medical Center	phase 2	Antiplatelet	P2Y12 receptor
prasugrel or ticagrelor	prasugrel or ticagrelor	University of Florida	marketed	P2Y12 receptor antagonist	P2Y12 receptor
Prasugrel Oral Tablet	Prasugrel Oral Tablet	Elliot Israel, MD	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Acetylsalicylic Acid + clopidogrel	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
enoxaparin + clopidogrel + aspirin	enoxaparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Factor Xa, Factor IIa, P2Y12 receptor, cyclooxygenase
clopidogrel (SR25990C)	clopidogrel (SR25990C)	Sanofi	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
heparin + clopidogrel + aspirin	heparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Antiplatelet and anticoagulant combination	Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet class)

Korea University Guro Hospital · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Syntrillo, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAPT, Statin — Competitive Intelligence Brief. https://druglandscape.com/ci/dapt-statin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab